GleamWall
中文EN

ALNY ALNYLAM PHARMACEUTICALS, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1178670 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY65.2%
TTM net income YoY239.7%
TTM EPS YoY206.9%
Revenue 3-yr CAGR53.0%
Net income 3-yr CAGR—

Margins

Gross margin81.8%
Operating margin13.5%
Net margin10.5%
FCF margin11.8%
EBITDA margin15.0%

Returns

ROE90.8%
ROA8.4%
ROIC (approx.)—
Asset turnover0.81x

Leverage & solvency

Liabilities / assets84.1%
Debt / equity0.00x
Current ratio2.76x
Interest coverage1.58x

Cash quality & payout

Operating cash flow / net income1.28x
Accruals ratio-2.3%
Payout ratio—
Capex / revenue1.6%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$3.71B$2.25B
Cost of revenue$677.17M$306.51M
Gross profit$3.04B$1.94B
R&D expense$1.32B$1.13B
SG&A expense$1.21B$975.53M
Operating income$501.58M-$176.88M
Interest expense$252.63M$141.86M
Pretax income$323.15M-$377.38M
Income tax$9.40M-$99.22M
Net income$313.75M-$278.16M
EBITDA$557.24M-$120.22M
EPS (basic)2.39-2.18
EPS (diluted)2.33-2.18
Weighted avg. shares (diluted)134.68M127.65M
Balance sheet
Cash & equivalents$1.66B$968.65M
Short-term investments$1.25B$1.72B
Receivables$777.57M$405.31M
Inventory$82.72M$78.51M
Current assets$4.05B$3.30B
PP&E, net$513.15M$502.78M
Total assets$4.97B$4.24B
Current liabilities$1.47B$1.19B
Total liabilities$4.18B$4.17B
Shareholders' equity$789.18M$67.09M
Shares outstanding132.38M129.29M
Cash flow statement
Operating cash flow$524.08M-$8.31M
Capital expenditure$58.70M$34.28M
Free cash flow$465.38M-$42.59M
Investing cash flow$436.33M-$116.84M
Financing cash flow-$305.19M$294.16M
Depreciation & amortization$55.66M$56.67M
Stock-based compensation$348.24M$272.08M

Free plan shows the latest 2 periods; Pro shows all 18 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.